細胞訊號傳導市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、產品、技術、途徑、地區和競爭格局分類，2021-2031年）

全球細胞訊號傳導市場預計將從 2025 年的 56.2 億美元成長到 2031 年的 88.5 億美元，複合年成長率為 7.86%。

此領域涵蓋種類繁多的試劑、儀器和耗材，用於解析調控重要細胞功能的複雜通訊網路。慢性疾病（尤其是癌症）發生率的不斷上升是推動該領域發展的主要動力。這導致對標靶治療的需求激增，而標靶療法依賴藥物研發中精準的通路識別。藥物研發領域的大量投資也為此進展提供了支持。例如，國際藥品製造商協會聯合會（IFPMA）發布的《2024年事實與數據》報告指出，製藥業將在2023年推出69種新的活性成分，這凸顯了在標靶檢驗和療效測試中對先進訊號傳導工具的需求。

儘管市場前景廣闊，但由於先進分析設備的高昂購置和維修成本，該市場仍面臨許多障礙。這些經濟障礙，加上解讀多重訊號資料的技術挑戰，可能會限制高通量技術在資源有限的研究機構和小規模學術實驗室中的廣泛應用。這些限制因素可能會阻礙先進訊號解決方案的普及，尤其是在預算較為緊張的新興市場。

市場促進因素

慢性病和自體免疫疾病發生率的上升推動了對能夠精確闡明訊號路徑的工具的需求，這也是全球細胞訊號傳導市場的主要驅動力。隨著癌症等疾病的日益普遍，對能夠檢驗特定生物標記和治療標靶的試劑和儀器的需求也日益成長。這一趨勢在腫瘤疾病的不斷增加中尤其明顯。根據美國癌症協會（ACS）發布的《2024年癌症事實與數據》報告，預計2024年美國新增癌症病例數將首次超過200萬例。因此，學術界和工業界的研究機構都在致力於細胞訊號傳導研究，以開發針對這些複雜生物學機制的標靶免疫療法和個人化醫療通訊協定。

同時，人工智慧和機器學習在細胞研究領域的應用正在重塑市場動態，簡化訊號傳導分析。製藥公司正積極利用運算工具建構複雜的訊號網路模型，有效加速藥物研發進程。這項策略轉變體現在巨額研發投入上；2024年2月，默克公司報告稱，其2023年的研發總支出將達到305億美元。為了最佳化這些投資，各公司都在積極尋求技術合作。例如，2024年1月，禮來公司宣布與Isomorphic Labs公司合作，簽署了一項協議，其中包括4,500萬美元的預付款，用於使用Isomorphic Labs的人工智慧平台來識別新型小分子療法。

市場挑戰

先進分析設備所需的大量投資是限制全球細胞訊號市場成長的主要障礙。購置和維護這些設備的高昂成本，對資金有限的小規模學術機構和生技公司而言構成了進入門檻。因此，這些機構往往會推遲購買整合式高通量系統，導致儀器整體銷售下降，並在價格敏感地區減緩市場擴張速度。這些資金限制使得小規模實驗室難以升級其技術基礎設施，市場影響力往往僅限於資金雄厚的研究中心。

現代藥物研發的巨額資金需求加劇了這項挑戰，迫使各機構在巨額營運支出和資本設備需求之間謹慎權衡。根據美國藥品研究與製造商協會 (PhRMA) 2024 年年度會員調查，會員公司在 2023 年的研發支出將達到 1,035 億美元。雖然這個數字代表著研發投入的蓬勃發展，但也凸顯了該產業在精簡支出方面面臨的巨大壓力。如果設備成本在如此緊張的預算下仍然居高不下，研究機構將被迫削減資本投資，這將直接阻礙關鍵訊號技術的廣泛應用。

市場趨勢

該領域的變革性趨勢包括空間生物學和多重成像平台的興起，使研究人員能夠觀察活體組織結構內的細胞訊號路徑。與犧牲空間背景的傳統批量定序方法不同，這些技術能夠繪製細胞間相互作用和訊號網路圖譜，這對於免疫腫瘤學中分析腫瘤微環境至關重要。這些工具的快速普及也反映在財務表現：2024年2月，10x Genomics公佈2023年總收入為6.187億美元，較上年成長20%，這主要得益於市場對空間分析設備的強勁需求。

同時，為了應對技術挑戰並最大限度地利用研發預算，製藥公司已採取策略性舉措，將複雜的訊號通路研究外包給受託研究機構(CRO)。隨著涉及高參數流式細胞技術和多組體學的檢測方法日益複雜，製藥公司優先考慮外部夥伴關係，而不是擴大內部基礎設施。這種方式使他們能夠在無需大量資本投入的情況下獲得專業知識。這種依賴程度如此之高，以至於查爾斯河實驗室 (Charles River Laboratories) 在 2024 年 2 月宣布，其藥物發現和安全性評估部門的收入達到 26.2 億美元，同比成長 6.9%，這主要得益於客戶對外部藥物發現能力的利用增加。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球細胞訊號傳導市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（內分泌訊號、旁分泌訊號、自分泌訊號、其他）
  • 依產品分類（消耗品、設備）
  • 依技術（流式細胞技術、顯微鏡、蛋白質印跡法、酵素連結免疫吸附試驗、其他）
  • 按通路（AKT訊息傳遞路徑、AMPK訊息傳遞路徑、ErbB/HER訊息傳遞路徑、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美細胞訊號傳導市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲細胞訊號傳導市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區細胞訊號傳導市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲細胞訊號傳導市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲細胞訊號傳導市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球細胞訊號傳導市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cell Signaling Technology, Inc.
• Danaher Corporation
• Merck KGaA
• PerkinElmer, Inc.
• Promega Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cell Signaling Market is projected to expand from USD 5.62 Billion in 2025 to USD 8.85 Billion by 2031, reflecting a compound annual growth rate of 7.86%. This sector comprises a diverse array of reagents, instruments, and consumables used to decode the intricate communication networks regulating essential cellular functions. Growth is primarily driven by the increasing incidence of chronic illnesses, particularly cancer, which has surged the demand for targeted therapies dependent on accurate pathway identification for drug development. This progression is supported by significant investment in pharmaceutical research and development; for example, the International Federation of Pharmaceutical Manufacturers & Associations noted in its 'Facts & Figures 2024' report that the industry launched 69 novel active substances in 2023, underscoring the need for advanced signaling tools in target validation and efficacy testing.

Despite these growth prospects, the market faces considerable obstacles due to the steep acquisition and upkeep costs associated with sophisticated analysis instrumentation. When combined with the technical difficulties inherent in interpreting multiplexed signaling data, these financial hurdles can limit the uptake of high-throughput technologies in research institutions with finite resources and smaller academic labs. Such constraints threaten to hinder the widespread adoption of advanced signaling solutions, particularly within emerging markets where budget limitations are more acute.

Market Driver

The escalating incidence of chronic and autoimmune conditions serves as a primary engine for the Global Cell Signaling Market, fueling the need for tools capable of precise pathway elucidation. As diseases like cancer become more prevalent, there is an intensified requirement for reagents and instruments that can validate specific biomarkers and therapeutic targets. This trajectory is highlighted by the rising burden of oncological conditions; the American Cancer Society's 'Cancer Facts & Figures 2024' report projected that new cancer cases in the United States would surpass 2 million for the first time in 2024. Accordingly, both academic and industrial laboratories are focusing heavily on cell signaling research to develop targeted immunotherapies and personalized medicine protocols that tackle these intricate biological mechanisms.

Concurrently, market dynamics are being reshaped by the incorporation of AI and Machine Learning into cellular research, which improves the efficiency of signal transduction analysis. Pharmaceutical companies are increasingly utilizing computational tools to model complex signaling networks, effectively speeding up drug discovery. This strategic pivot is reflected in massive R&D spending; Merck & Co. reported in February 2024 that their total research and development expenses hit $30.5 billion in 2023. To optimize these investments, firms are entering technical alliances, such as Eli Lilly and Company's January 2024 announcement of a collaboration with Isomorphic Labs, involving a $45 million upfront payment to utilize artificial intelligence platforms for identifying new small molecule therapeutics.

Market Challenge

The significant investment required for sophisticated analysis instrumentation acts as a major hurdle to the growth of the Global Cell Signaling Market. The high costs associated with acquiring and maintaining equipment establish a formidable barrier to entry for smaller academic institutions and biotechnology companies with limited financial resources. As a result, these entities frequently delay purchasing integrated high-throughput systems, which diminishes overall equipment sales and slows market expansion in price-sensitive areas. These financial limitations restrict smaller laboratories from upgrading their technical infrastructure, effectively confining the market's reach to well-funded research hubs.

This challenge is intensified by the financial demands of modern pharmaceutical research, where organizations must weigh massive operational expenses against capital equipment requirements. The Pharmaceutical Research and Manufacturers of America reported in its '2024 PhRMA Annual Membership Survey' that member companies spent USD 103.5 billion on research and development in 2023. Although this figure suggests a vibrant sector, it also highlights the immense pressure on the industry to streamline expenditures. When the cost of instruments remains prohibitively high in the context of these strict budget allocations, research facilities are forced to curb capital spending, directly impeding the wider adoption of essential signaling technologies.

Market Trends

A transformative trend in the sector is the rise of spatial biology and multiplexed imaging platforms, which enable researchers to observe cell signaling pathways within their native tissue structure. In contrast to traditional bulk sequencing methods that sacrifice spatial context, these technologies map cellular interactions and signal transduction networks, a capability essential for analyzing the tumor microenvironment in immuno-oncology. The rapid uptake of these tools is reflected in financial performance; 10x Genomics reported in February 2024 that its total revenue for 2023 reached $618.7 million, a 20% increase from the previous year attributed to strong demand for spatial instrumentation.

Simultaneously, there is a strategic movement toward outsourcing complex signaling studies to Contract Research Organizations (CROs) as a means to manage technical difficulties and maximize research budgets. As assays involving high-parameter flow cytometry and multi-omics grow more intricate, pharmaceutical firms are favoring external partnerships over the expansion of internal infrastructure. This approach provides access to specialized expertise without necessitating heavy capital investment. The magnitude of this reliance is significant; Charles River Laboratories announced in February 2024 that its Discovery and Safety Assessment segment generated $2.62 billion in revenue, a 6.9% increase from the prior year, as clients increasingly utilized external discovery capabilities.

Key Market Players

• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cell Signaling Technology, Inc.
• Danaher Corporation
• Merck KGaA
• PerkinElmer, Inc.
• Promega Corporation

Report Scope

In this report, the Global Cell Signaling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Signaling Market, By Type

• Endocrine Signaling
• Paracrine Signaling
• Autocrine Signaling
• Others

Cell Signaling Market, By Product

• Consumables
• Instruments

Cell Signaling Market, By Technology

• Flow Cytometry
• Microscopy
• Western Blotting
• ELISA
• Others

Cell Signaling Market, By Pathway

• AKT Signaling Pathway
• AMPK Signaling Pathway
• ErbB/HER Signaling Pathway
• Others

Cell Signaling Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Signaling Market.

Available Customizations:

Global Cell Signaling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Signaling Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Endocrine Signaling, Paracrine Signaling, Autocrine Signaling, Others)
  • 5.2.2. By Product (Consumables, Instruments)
  • 5.2.3. By Technology (Flow Cytometry, Microscopy, Western Blotting, ELISA, Others)
  • 5.2.4. By Pathway (AKT Signaling Pathway, AMPK Signaling Pathway, ErbB/HER Signaling Pathway, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Cell Signaling Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Technology
  • 6.2.4. By Pathway
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Signaling Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By Pathway
  • 6.3.2. Canada Cell Signaling Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By Pathway
  • 6.3.3. Mexico Cell Signaling Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By Pathway

7. Europe Cell Signaling Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Technology
  • 7.2.4. By Pathway
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Signaling Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By Pathway
  • 7.3.2. France Cell Signaling Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By Pathway
  • 7.3.3. United Kingdom Cell Signaling Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By Pathway
  • 7.3.4. Italy Cell Signaling Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By Pathway
  • 7.3.5. Spain Cell Signaling Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By Pathway

8. Asia Pacific Cell Signaling Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Technology
  • 8.2.4. By Pathway
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Signaling Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By Pathway
  • 8.3.2. India Cell Signaling Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By Pathway
  • 8.3.3. Japan Cell Signaling Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By Pathway
  • 8.3.4. South Korea Cell Signaling Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By Pathway
  • 8.3.5. Australia Cell Signaling Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By Pathway

9. Middle East & Africa Cell Signaling Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Technology
  • 9.2.4. By Pathway
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Signaling Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By Pathway
  • 9.3.2. UAE Cell Signaling Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By Pathway
  • 9.3.3. South Africa Cell Signaling Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By Pathway

10. South America Cell Signaling Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Technology
  • 10.2.4. By Pathway
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Signaling Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By Pathway
  • 10.3.2. Colombia Cell Signaling Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By Pathway
  • 10.3.3. Argentina Cell Signaling Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By Pathway

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Signaling Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN N.V.
• 15.3. Becton, Dickinson and Company
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Bio-Techne Corporation
• 15.6. Cell Signaling Technology, Inc.
• 15.7. Danaher Corporation
• 15.8. Merck KGaA
• 15.9. PerkinElmer, Inc.
• 15.10. Promega Corporation

16. Strategic Recommendations

17. About Us & Disclaimer